The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 3×
“EGFR NSCLCa Gefitinib, erlotinib Monotherapy Shepherd et al. (2005)32,b, Taron et al. (2005)35, Lynch et al. (2004)36”
BackgroundInfluentialTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & Harmon, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j · Cited by 2,132
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Self-citationGefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S., Danenberg, K., Domenichini, I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,551
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Stable suppression of tumorigenicity by virus-mediated RNA interference
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00122-8 · Cited by 886
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade
Berman, D. M., Karhadkar, S. S., Hallahan, A. R., Pritchard, J. I., Eberhart, C. G., Watkins, D. N., Chen, J. K., Cooper, M. K., Taipale, J., Olson, J. M., et al. (2002) · Science · doi:10.1126/science.1073733 · Cited by 803
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
The transcriptional repressor Snail promotes mammary tumor recurrence
Moody, S. E., Perez, D., Pan, T.-C., Sarkisian, C. J., Portocarrero, C. P., Sterner, C. J., Notorfrancesco, K. L., Cardiff, R. D., & Chodosh, L. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.009 · Cited by 750
Biological networks: the tinkerer as an engineer
Alon, U. (2003) · Science · doi:10.1126/science.1089072 · Cited by 706
A resource for large-scale RNA-interference-based screens in mammals
Paddison, P. J., Silva, J. M., Conklin, D. S., Schlabach, M., Li, M., Aruleba, S., Balija, V., O'Shaughnessy, A., Gnoj, L., Scobie, K., et al. (2004) · Nature · doi:10.1038/nature02370 · Cited by 695
Self-Renewal and Cancer of the Gut: Two Sides of a Coin
Radtke, F., & Clevers, H. (2005) · Science · doi:10.1126/science.1104815 · Cited by 690
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 626
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 490
Huang, S. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900023 · Cited by 439
D'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., et al. (2001) · Nature Medicine · doi:10.1038/84691 · Cited by 418
Reversibility of acute B-cell leukaemia induced by BCR–ABL1
Huettner, C. S., Zhang, P., Van Etten, R. A., & Tenen, D. G. (2000) · Nature Genetics · doi:10.1038/71691 · Cited by 413
Ottino, J. M. (2004) · Nature · doi:10.1038/427399a · Cited by 351
Cancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D., & Chodosh, L. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00212-x · Cited by 345
Taron, M., Ichinose, Y., Rosell, R., Mok, T., Massuti, B., Zamora, L., Mate, J. L., Manegold, C., Ono, M., Queralt, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2618 · Cited by 334
Verma, U. N., Surabhi, R. M., Schmaltieg, A., Becerra, C. R., & Gaynor, R. B. (2003) · PubMed · Cited by 328
Frantz, S. (2005) · Nature · doi:10.1038/437942a · Cited by 322
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
Cancer Invasion and Metastasis
Wittekind, C., & Neid, M. (2005) · Oncology · doi:10.1159/000086626 · Cited by 269
Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis
Weinstein, I. B. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.857 · Cited by 268
Self-citationMechanism of action of anti-HER2 monoclonal antibodies
Baselga, J., & Albanell, J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s35 · Cited by 265
Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.
Arber, N., Doki, Y., Han, E. K.-H., Sgambato, A., Zhou, P., Kim, N. H., Delohery, T. M., Klein, M. G., Holt, P. R., & Weinstein, I. B. (1997) · PubMed · Cited by 226
Self-citationMiller, A. J., Du, J., Rowan, S., Hershey, C. L., Widlund, H. R., & Fisher, D. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2440 · Cited by 214
Molecular Networks: The Top-Down View
Bray, D. (2003) · Science · doi:10.1126/science.1089118 · Cited by 214
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis
Gunther, E. J., Moody, S. E., Belka, G. K., Hahn, K. T., Innocent, N., Dugan, K. D., Cardiff, R. D., & Chodosh, L. A. (2003) · Genes & Development · doi:10.1101/gad.1051603 · Cited by 214
Rosée, P. G. L., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., & Druker, B. J. (2002) · PubMed · Cited by 203
The disparate role of BMP in stem cell biology
Varga, A. C., & Wrana, J. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208919 · Cited by 197
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
Balch, C., Yan, P. S., Craft, T. R., Young, S. R. L., Skalnik, D. G., Huang, T. H. ‐., & Nephew, K. P. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0216 · Cited by 151
Zhou, P., Jiang, W. B., Yj, Z., Sm, K., Schieren, I., Rm, S., & Ib, W. (1995) · PubMed · Cited by 141
Targeted agents for the treatment of advanced renal cell carcinoma
Stadler, W. M. (2005) · Cancer · doi:10.1002/cncr.21453 · Cited by 134
Jonkers, J., & Berns, A. J. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.002 · Cited by 133
Mills, G. B., Lu, Y., & Kohn, E. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191379498 · Cited by 126
Weinstein, I. B., Begemann, M., Zhou, P., Han, E. K.-H., Sgambato, A., Doki, Y., Arber, N., Ciaparrone, M., & Yamamoto, H. (1997) · PubMed · Cited by 125
Self-citationHui, A. B., Or, Y. Y., Takano, H., Tsang, R. K., To, K., Guan, X., Sham, J. S., Hung, K., Lam, C. N. Y., van Hasselt, C. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0648 · Cited by 115
Kornmann, M., Danenberg, K. D., Arber, N., Beger, H. G., Danenberg, P. V., & Korc, M. (1999) · PubMed · Cited by 113
Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.
Sauter, E. R., Nesbit, M., Litwin, S., Klein–Szanto, A. J., Cheffetz, S., & Herlyn, M. (1999) · PubMed · Cited by 110
Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma.
Li, K., Lin, S., Brunicardi, F. C., & Seu, P. (2003) · PubMed · Cited by 106
Colomer, R., Lupu, R., Bacus, S. S., & Gelmann, E. P. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.405 · Cited by 99
Zhang, S., Pan, F., Xu, J., Yuan, J. J., Guo, S.-Y., Dai, G., Xue, B., Shen, W., Wen, C., Zhao, D., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0106 · Cited by 81
Fan, Q.-W., Specht, K. M., Zhang, C., Goldenberg, D. D., Shokat, K. M., & Weiss, W. A. (2003) · PubMed · Cited by 76
Brief Communication: A New Combination in the Treatment of Advanced Pancreatic Cancer
Moore, M. J. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.017 · Cited by 64
Genomics and proteomics—the way forward
Baak, J. P. A., Janssen, E. A. M., Søreide, K., & Heikkilæ, R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi728 · Cited by 30
The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy
Dowell, J. E., & Minna, J. D. (2004) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0007 · Cited by 18
Cited by
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
Ouyang, L., Shi, Z., Zhao, S., Wang, F. ‐., Zhou, T. ‐., Liu, B., & Bao, J. ‐. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00845.x · Cited by 1,452
Metadata
- Authors
- Weinstein, I. B., & Joe, A. K.
- Venue
- Nature Clinical Practice Oncology
- Published
- 2006-08
- Volume
- 3
- Issue
- 8
- Pages
- 448-457
- ISSN
- 1743-4254 (ISSN-L)
- 1743-4262
- OpenAlex
- W2147960762
- Cited by
- 705
- References
- 74
- FWCI
- 29.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.